EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort

Eva Gerbier iD, Guillaume Favre iD, Emeline Maisonneuve iD, Michael Ceulemans iD, Ursula Winterfeld iD, Kim Dao iD, Christian P R Schmid, Stephen P Jenkinson, Bartlomiej Niznik, David Baud iD, Julia Spoendlin iD, Alice Panchaud iD

Journal of Diabetes Research · 2023

DOI: 10.1155/2023/4105993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Research, 2023. Verfasst von Eva Gerbier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service of Pharmacy, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Diabetes, Gestational, Metformin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LOA IV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence of diabetes mellitus (both pregestational and gestational) is increasing worldwide, and hyperglycemia during pregnancy is associated with adverse pregnancy outcomes. Evidence on the safety and efficacy of metformin during pregnancy has accumulated resulting in an increase in its prescription in many reports.

Aims

We aimed to determine the prevalence of antidiabetic drug use (insulins and blood glucose-lowering drugs) before and during pregnancy in Switzerland and the changes therein during pregnancy and over time.

Methods

We conducted a descriptive study using Swiss health insurance claims (2012-2019). We established the MAMA cohort by identifying deliveries and estimating the last menstrual period. We identified claims for any antidiabetic medication (ADM), insulins, blood glucose-lowering drugs, and individual substances within each class. We defined three groups of pattern use based on timing of dispensation: (1) dispensation of at least one ADM in the prepregnancy period and in or after trimester 2 (T2) (pregestational diabetes); (2) dispensation for the first time in or after T2 (GDM); and (3) dispensation in the prepregnancy period and no dispensation in or after T2 (discontinuers). Within the pregestational diabetes group, we further defined continuers (dispensation for the same group of ADM) and switchers (different ADM group dispensed in the prepregnancy period and in or after T2).

Results

MAMA included 104,098 deliveries with a mean maternal age at delivery of 31.7. Antidiabetic dispensations among pregnancies with pregestational and gestational diabetes increased over time. Insulin was the most dispensed medication for both diseases. Between 2017 and 2019, less than 10% of pregnancies treated for pregestational diabetes continued metformin rather than switching to insulin. Metformin was offered to less than 2% of pregnancies to treat gestational diabetes (2017-2019).

Conclusion

Despite its position in the guidelines and the attractive alternative that metformin represents to patients who may encounter barriers with insulin therapy, there was reluctance to prescribe it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalMetforminPregnancyFemaleHumansSwitzerlandBlood GlucoseHypoglycemic AgentsInsulinPregnancy OutcomeGlucose

Substanzen

Blood GlucoseHypoglycemic AgentsMetforminInsulinGlucose

Autor:innen und Institutionen

  • Service of Pharmacy, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Materno-Fetal and Obstetrics Research Unit, Department "Woman-Mother-Child", Lausanne University Hospital, 1011 Lausanne, Switzerland.
  • Institute of Primary Health Care (BIHAM), University of Bern, 3012 Bern, Switzerland.
  • Teratology Information Service, Pharmacovigilance Centre Lareb, 's-Hertogenbosch, 5237 MH Hertogenbosch, Netherlands.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
  • L-C&Y, KU Leuven Child and Youth Institute, 3000 Leuven, Belgium.

ORCID-Profile: Eva Gerbier, Guillaume Favre, Emeline Maisonneuve, Michael Ceulemans, Ursula Winterfeld, Kim Dao, David Baud, Julia Spoendlin, Alice Panchaud

Förderung

  • LOA IV

Zitieren

APA

Gerbier, E., Favre, G., Maisonneuve, E., Ceulemans, M., Winterfeld, U., Dao, K., Schmid, C. P. R., Jenkinson, S. P., Niznik, B., Baud, D., Spoendlin, J., & Panchaud, A. (2023). Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort. Journal of Diabetes Research. https://doi.org/10.1155/2023/4105993

Vancouver

Gerbier E, Favre G, Maisonneuve E, Ceulemans M, Winterfeld U, Dao K, et al. Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort. Journal of Diabetes Research. 2023. doi:10.1155/2023/4105993

BibTeX
@article{Gerbier2023,
  author = {Gerbier, Eva and Favre, Guillaume and Maisonneuve, Emeline and Ceulemans, Michael and Winterfeld, Ursula and Dao, Kim and Schmid, Christian P R and Jenkinson, Stephen P and Niznik, Bartlomiej and Baud, David and Spoendlin, Julia and Panchaud, Alice},
  title = {Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort},
  journal = {Journal of Diabetes Research},
  year = {2023},
  doi = {10.1155/2023/4105993}
}
Kostenlos starten →